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Abstract
Background: Needle and syringe programmes (NSP) are a critical component of harm reduction interventions among
people who inject drugs (PWID). Our primary objective was to summarize the evidence on the effectiveness of NSP for
PWID in reducing blood-borne infection transmission and injecting risk behaviours (IRB).
Methods: We conducted an overview of systematic reviews that included PWID (excluding prisons and consumption
rooms), addressed community-based NSP, and provided estimates of the effect regarding incidence/prevalence of
Human Immunodeficiency Virus (HIV), Hepatitis C virus (HCV), Hepatitis B virus (HBV) and bacteremia/sepsis, and/or
measures of IRB. Systematic literature searches were undertaken on relevant databases, including EMBASE, MEDLINE,
and PsychINFO (up to May 2015). For each review we identified relevant studies and extracted data on methods, and
findings, including risk of bias and quality of evidence assessed by review authors. We evaluated the risk of bias of each
systematic review using the ROBIS tool. We categorized reviews by reported outcomes and use of meta-analysis; no
additional statistical analysis was performed.
Results: We included thirteen systematic reviews with 133 relevant unique studies published between 1989 and 2012.
Reported outcomes related to HIV (n = 9), HCV (n = 8) and IRB (n = 6). Methods used varied at all levels of design and
conduct, with four reviews performing meta-analysis. Only two reviews were considered to have low risk of bias using
the ROBIS tool, and most included studies were evaluated as having low methodological quality by review authors. We
found that NSP was effective in reducing HIV transmission and IRB among PWID, while there were mixed results
regarding a reduction of HCV infection. Full harm reduction interventions provided at structural level and in
multi-component programmes, as well as high level of coverage, were more beneficial.
Conclusions: The heterogeneity and the overall low quality of evidence highlights the need for future community-level
studies of adequate design to support these results.
Trial registration: The protocol of this systematic review was registered in Prospective Register of Systematic Reviews
(PROSPERO 2015:CRD42015026145).
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Background
People who inject drugs (PWID) experience high levels of
morbidity and mortality. Drug-related harms include over-
dose, drug-related deaths, and blood-borne infections
such as Human Immunodeficiency Virus (HIV), Hepatitis
C (HCV), Hepatitis B (HBV), and bacteremia/sepsis. HCV
is currently the most prevalent infectious disease affecting
PWID, while HIV prevalence rates are lower. In an esti-
mated total of 12.7 to 16 million PWID worldwide, it is
believed that 1.2 million are infected with HIV [1] and 10
million are infected with HCV [2]. Sharing needles and
syringes, as well as other injecting paraphernalia, is a key
route of transmission of these infections [3].
Needle and syringe programmes (NSP) are thought to
be a critical component of harm reduction interventions
among PWID [3, 4]. The first NSP was established in the
1980s [5], in response to the global HIV epidemic, with
the goal of providing access and encouraging the use of
sterile injection paraphernalia by PWID. Since then,
provision of these services has grown rapidly. Importantly,
a shift in paradigm has favoured NSP as components of
harm reduction or harm minimization policies, which
focus on reducing all drug-related harms, i.e. preventing
HIV, HBV and HCV infection, minimizing needle and
syringe sharing and reuse, reducing the volume of dis-
carded needles and syringes in the environment, and fa-
cilitating access to sterile paraphernalia. Furthermore,
NSP may also promote the use of condoms and provide
opportunistic relevant health information and services [3].
NSP are complex health interventions with several
interacting components, such as behavioural changes in
PWID and providers, a complex operating framework
(users, providers, setting, health systems), and some
degree of flexibility of interventions [6]. There is consid-
erable variability among regions and countries in service
provision, coverage and range of harm reduction inter-
ventions offered by NSP. In particular, a variety of
measures have been developed to improve access to and
use of sterile injecting equipment and to increase users’
choice. These include several methods of distribution or
sale such as conventional NSP in fixed-sites, pharmacy-
based distribution, dispensing machines and outreach
programmes – often using a mobile van or bus, or
through home-visits [3]. Generally, pharmacy and
specialist needle exchange provides a wide range of
harm reduction information and advice, along with clean
needles and syringes and possibly injecting parapherna-
lia. The legal framework in which NSP operate also
varies at country level [7]. Pharmacy-based NSP are known
to be in place in at least Australia [8], Belgium, France,
Ireland, Kyrgyzstan, the Netherlands, Portugal, Spain,
Slovenia, Ukraine [7, 9], UK [10], and New Zealand [11].
Many systematic reviews on the effectiveness of inter-
ventions providing injecting equipment have been
conducted to date. Overviews of reviews which compile
information from these multiple systematic reviews, have
also been published. The aim of these overviews is to
provide end-users with a comprehensive and critical
summary of the available evidence on this intervention.
Overviews are of particular interest in this field because
existing systematic reviews have focused on disparate
questions, regarding either specific populations (e.g.
country-specific evidence), specific types of interventions
(e.g. different types of NSP provision) or, most
commonly, specific outcomes (e.g. HIV or HCV trans-
mission) [12–14]. Furthermore, there is variability in
methods used in these systematic reviews, including the
assessment of possible biases and the use of quantitative
synthesis (meta-analysis). Nevertheless, to the best of
our knowledge, the published overviews in this field
have focused only on specific outcomes, i.e. transmission
of HIV and/or HCV.
Objectives
Our primary objective was to conduct an overview of
systematic reviews that evaluated the evidence of the
effectiveness of NSP for PWID across a range of differ-
ent relevant outcomes, i.e. blood-borne infection trans-
mission and injecting risk behaviours (IRB).
Our secondary objective was to assess how different
aspects of NSP provision, including provider, setting,
coverage and any related component delivered in
parallel, such as harm reduction services and opiate
substitution therapy, modified the effect of NSP, with a
particular focus on pharmacy-driven NSP.
Methods
We followed current guidance on the conduct of
overviews of reviews, including recommendations from
the Cochrane Collaboration [15] and guidance on
public health intervention reviews by the Centre for
Reviews and Dissemination of the University of York
[16]. We also followed the recommendations from the
PRISMA-P statement regarding reporting items that we
considered applicable to this overview [17]. The protocol
for this overview was registered at PROSPERO
(CRD42015026145) available at http://www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42015026145.
Eligibility criteria
For inclusion in this overview, studies had to meet the
following criteria:
1. Study design: systematic reviews, operationally defined
as studies reporting a clearly stated set of objectives,
eligibility criteria, a systematic search using two or
more sources, a systematic presentation of the
characteristics and findings of the included studies,
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and estimates of the size and direction of the effect of
interventions presented as numerical data, on an
individual study-level basis and/or with quantitative
synthesis (meta-analysis);
2. Participants: PWID, defined as people who inject
some form of drug at the beginning of the study.
We excluded studies focusing exclusively on participants
whose consumption was confined to prisons and
consumption rooms, since these are populations with
distinct characteristics from our target population;
3. Interventions: systematic reviews had to evaluate
community-based NSP, defined as the supply of at
least needles and syringes, with or without other
injecting paraphernalia for the preparation and
consumption of drugs;
4. Outcomes: required reported outcomes included the
incidence and/or prevalence of blood-borne infections
(HIV, HCV, HBV and bacteremia/sepsis), and/or
measures of IRB (including but not limited to syringe
re-use, borrowing, sharing, renting and lending).
When more than one review included exactly the same
studies, the review that reported the most complete presen-
tation of results was selected for inclusion in the overview.
Search strategy and screening
Searches were undertaken on MEDLINE®In-Process &
Other Non-Indexed Citations (from 1946 to 12th of
May 2015), EMBASE (from 1974 to 12th of May 2015)
and PsycINFO (from 1806 to 12th of May 2015) via the
OVID SP interface. In addition, the following databases
were searched: the NHS Economic Evaluation Database
(NHS EED), the Database of Abstracts of Reviews of
Effects (DARE), the Cochrane Database of Systematic
Reviews (CDSR), the National Institute for Health and
Clinical Excellence (NICE), the Campbell Library of
Systematic Reviews and the Database of Promoting Health
Effectiveness Reviews (DoPHER). The search strategies for
each database are shown in a supplementary file
(Additional file 1). No language or other types of restric-
tions were applied. In addition to the database searches,
handsearching of the references of the included reviews
was undertaken to identify further relevant studies.
Titles and abstracts of articles identified were screened
independently by two authors (MC, JA), and classified as
include, unclear or exclude. The full reports of all
articles that classified as include or unclear were then
obtained, and two authors (MC, GD) examined compli-
ance of reviews with eligibility criteria, with a third
author acting as an arbiter (RF).
Data extraction
Data from reports of all included systematic reviews
were extracted by two authors (MC, GD) and validated
by a third author (RF), using a data extraction form
designed and pre-piloted for this overview. The follow-
ing general characteristics were extracted from each
systematic review: publication details; study objectives;
eligibility criteria (population, intervention, comparators,
outcomes, study designs); any reported protocol; and
methods used for search, screening, data extraction and
synthesis. For each systematic review, we listed all in-
cluded studies and evaluated whether they matched the
eligibility criteria for this overview regarding population,
interventions and outcomes. We then extracted the
following results from the eligible group of studies,
whenever reported at the systematic review level: study
design; countries involved; characteristics of included
participants (demographics, prevalence of HIV/HCV);
description of interventions and any co-intervention,
duration of intervention and follow-up; effect estimates
from meta-analysis (if available) or at individual study-
level, for each relevant outcome; and any subgroup or
sensitivity analyses. The authors’ conclusions for each
relevant outcome were also collected. We contacted the
authors of reviews for relevant missing data.
Assessment of methodological quality
At a study level, we extracted data on any risk of bias
assessments of primary studies when performed and re-
ported by reviewers in each systematic review, including
tools used and summarized results. We also collected
data on any reported evaluations of the quality of
evidence concerning our outcomes of interest in
included reviews, particularly those using the Grading of
Recommendations Assessment, Development and Evalu-
ation (GRADE) tool [18], as well as data on assessments
of publication bias.
At a systematic review level, we assessed the methodo-
logical quality of each included systematic review using
the Risk Of Bias In Systematic Reviews (ROBIS) tool [19].
Two review authors (MC, RF) performed quality assess-
ments independently, using piloted decision rules. Dis-
agreements regarding overall assessments were resolved
through discussion, with a third reviewer serving as the
final arbitrator (AVC). The rationale behind assessments
was documented. We calculated measures of agreement
and reliability between raters for each ROBIS domain.
Data synthesis
We stratified the included systematic reviews by: (i) type
of outcomes assessed (blood-borne infections, IRB), and
(ii) type of analysis (with or without meta-analysis). We
summarized data from the included reviews both in text
and in summary tables and figures. When meta-analysis
was performed, we report pooled estimates using the
models and measures of effect reported by systematic re-
view authors, with 95% confidence intervals (95% CI);
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we did not perform any additional statistical analysis.
When reported, the accompanying I2 values, which
describe the percentage of total variation across studies
that is due to heterogeneity rather than chance, were
collected [20].
Results
The search and screening process is summarised in
Fig. 1. A total of 667 citations were identified through
the various database searches. Three additional re-
cords were identified in the reference lists of screened
studies. After 37 duplicates were removed, we obtained
633 citations, which were screened by title and abstract.
We excluded 582 citations as they did not meet the inclu-
sion criteria, and the remaining 51 were screened full text.
Thirty-five citations were further excluded, and two
reports [21, 22] were unobtainable. Fourteen reports
were thus included, corresponding to 13 systematic
reviews, as two records referred to the same study
[12, 23]. Within those publications three were reports
from National Institutes/Expert Commitees in the US
[24], UK [12] and Canada [25], while 10 were regular
papers published in scientific journals.
Description of included reviews
Table 1 lists the key characteristics of the 13 included
systematic reviews that evaluated the evidence of the
effectiveness of NSP for PWID in the community set-
ting. We classified reviews by type of outcomes reported
and type of data analysis (Fig. 2).
The number of databases searched per review varied
between two and 15, with the three most common
sources being MEDLINE, EMBASE and PsycINFO. The
dates of last search varied between 1995 [26] and 2012
[27]. Of 287 studies included in these 13 reviews, 200
studies matched the eligibility criteria for this overview,
corresponding to 133 unique studies (a matrix with
included studies by review is available in a supplemen-
tary file: Additional file 2). We included the complete set
of studies from four reviews, as in the remaining reviews at
least one study did not fulfill our eligibility criteria [27–30].
The number of relevant studies included per review ranged
from three [31, 32] to 43 [24]. While there was some
overlap in the included studies between reviews, the major-
ity (68%) was included in one review only.
We found substantial variability in the criteria used by
review authors to define and classify study designs, as well
Fig. 1 Screening decisions up to date as of 30Jun2015. Original search date 12May2015
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as types of designs of included studies. Only four reviews
specified the types of study design in their eligibility
criteria [12, 26, 29, 33]. Three reviews included random-
ized controlled trials (four RCTs overall) [12, 26, 31], while
the remaining reviews included cohorts and case-controls
(101 overall), as well as other study designs (time series,
before/after studies or ecological studies) (95 overall).
Three of the included reviews were restricted to
studies conducted in specific countries or economic re-
gions (China, UK, and low- and middle-income countries)
[28, 31, 32]. Nine reviews reported data on HIV, eight on
HCV, and six on IRB. Seven reviews evaluated more than
one of these outcomes. Four reviews used meta-analysis
[26, 27, 32, 34], one of which using individual-participant
data [32]. The remaining nine reviews used narrative
synthesis [12, 24, 25, 28–31, 33, 35]. The reasons reported
by the authors for conducting or not conducting
meta-analysis varied between reviews, even when there
was a degree of overlap between included studies.
Methodological quality
Seven reviews reported having assessed the methodo-
logical quality of included studies [12, 24, 25, 27, 29, 33, 34].
In two reviews the authors developed ad hoc tools [33, 34],
while the remaining reviews used previously existing
instruments, often with modifications (tools used:
Newcastle-Ottawa, GRADE, WHO-Johns Hopkins 9-
Point Rigour Scale, Quality assessment tools devel-
oped by NICE Centre for Public Health Excellence,
England and Wales and the Effective Public Health
Practice Project, Canada) [12, 24, 25, 27, 29]. Only
two instruments were used more than once, and all
other instruments varied. Not all reviews reported the
results of these assessments; when reported, most
studies were considered to have low methodological
quality, given methodological weaknesses and biases
related to observational study designs. Only one
quantitative review [27] incorporated quality in data
synthesis, by conducting a sensitivity analysis. In
reviews without meta-analysis, methodological quality
and risk of bias was presented descriptively in the
interpretation of study results. Two reviews [24, 27]
reported using the GRADE tool to assess the quality
of the body of evidence. One considered the overall
quality of evidence as low [27], while the other, using
an adaptation of GRADE, evaluated the quality of
Fig. 2 Studies selected for inclusion classified by outcome(s) reported and strategy for data synthesis. *Grey shaded boxes represent the outcome
reported in the reviews indicated in the right column. “HIV”, ”HCV” and “Injecting risk behaviours” is used to classify the reviews that reported the
impact of NSP in the number of HIV infections, number of HCV infections and change in injection behavior. The reviews are also presented in the
right column by strategy used for data synthesis
Fernandes et al. BMC Public Health  (2017) 17:309 Page 7 of 15
evidence as modest to moderate for different out-
comes [24].
Using the ROBIS tool, only two of the included reviews
were considered to have low risk of bias, whereas the
remaining were considered to have either high (n = 8) or
unclear risk of bias (n = 3) (summary of results available in
a supplementary file: Additional file 3). The majority of re-
views were rated as having high or unclear risk of bias
across all ROBIS domains, i.e. study eligibility criteria, iden-
tification and selection of studies, data collection and study
appraisal, synthesis and findings. Percentage of agreement
between ROBIS raters varied between 77% and 92%, and
weighted kappa (quadratic) between 0.82 and 0.95.
The results from the PRISMA-P statement applied to
this overview are presented at Additional file 4.
Effects of NSP
HIV prevalence and/or incidence
Of nine reviews that reported data on HIV outcomes,
two were at low risk of bias [12, 27], and only one
performed meta-analysis [27]. The proportion of studies
included in only one of these nine reviews was 71%.
Reviews with meta-analysis The most recent review by
Aspinall et al. included twelve studies (10 cohort, one
case-control and one cross-sectional study), and was
evaluated as having low risk of bias. The review reported
a 34% “risk” reduction of HIV transmission (pooled
effect estimate of 0.66; 95% CI: 0.43 to 1.01; n = 10
studies; I2 = 76%) in individuals exposed to NSP, com-
pared with those who were not, or were less frequently,
exposed to NSP. This estimate was obtained by pooling
both adjusted and unadjusted effect sizes regardless of
study design, in a random effects model, and pooling all
types of effect measures (odds ratio, risk ratio, hazard
ratio). Sensitivity analyses supported these results, with a
statistically significant reduction in HIV transmission
associated with NSP exposure in both higher quality stud-
ies (0.42; 95% CI: 0.22 to 0.81), and studies reporting rela-
tive risks or hazard ratios (0.60; 95% CI: 0.37 to 0.97).
Subgroup analyses showed that studies using sequential
follow-up (i.e. groups exposed to NSP and groups not ex-
posed followed sequentially, and not concurrently) and
studies recruiting post-1990 had lower effect estimates
(0.21 [95% CI: 0.11 to 0.41] and 0.52 [95% CI: 0.28 to
0.95], respectively). Further, studies comparing 100% NSP
coverage (i.e. clean needle and syringe used for 100% of
injections) with <100% NSP coverage generated a pooled
effect estimate of 0.58 (95% CI: 0.22 to 1.57). Quality of
evidence was considered low using GRADE, and most of
these results had substantial heterogeneity.
Reviews without meta-analysis The quantitative results
presented above are supported by most reviews with
qualitative summaries of the evidence only, all of which
published between 1999 and 2013. Differences between
reviews could be found regarding eligibility criteria (e.g.
type of NSP, population- vs individual-level outcomes,
study design), search and screening methods, quality
assessments and interpretation of study results. In most
of these reviews, the authors described and contextual-
ized results from each individual study or group of
studies regarding HIV outcomes. Some reviews used
vote counting to compare the number of positive studies
with reduction in HIV transmission, with the number of
negative studies. In the following paragraphs, we present
the main results of these reviews, starting with those
focusing on the impact of different aspects of NSP
provision followed by results of reviews focusing exclu-
sively on the comparison between NSP andno NSP.
Regarding aspects of NSP provision, Jones and
colleagues reported results from a recent systematic re-
view classified as low risk of bias, that focused on level
of coverage, syringe dispensation policies, type of NSP,
provision of additional harm-reduction services and of
opiate substitution therapy [12]. Authors judged that the
range of study designs, intervention approaches exam-
ined and outcomes precluded the use of meta-analysis.
Only three studies focused on HIV outcomes. A low-qu-
ality study showed no significant trend for HIV preva-
lence when comparing primary sources of needles
(pharmacies, fixed site NSP and van-based NSP),
although HIV prevalence was lower among pharmacy
users than in participants who reported using van or
fixed site NSP (16% vs. 21% and 25%, respectively,
p = 0.16) [36]. Another study [37] included in this
review examined the impact of dispensation policies,
and noted a decrease in HIV prevalence (based on test-
ing or self-report) between the period of legal pharmacy
syringe purchase and when up to five needles could be
exchanged at newly established NSP (35% to 22%;
p < 0.05). Finally, one moderate quality cohort study
[38] also included in the review by Jones and colleagues
evaluated different levels of harm reduction and found
that a full harm reduction strategy (combination of
methadone treatment and full participation in NSP)
reduced the incidence of HIV when compared to incom-
plete or no harm reduction (incidence rate ratio: 0.32;
95% CI: 0.17 to 0.62).
In line with these results, a review with an overall
unclear risk of bias by Abdul-Quader et al. [29] identi-
fied studies with structural-level NSP, ie interventions in
which changes in policy and legal environment have
facilitated an increased availability of sterile syringes,
and focused on population-level outcomes. The oper-
ational definition of structural-level NSP was a
minimum 50% coverage of PWID and distribution of 10
or more needles/syringe per PWID per year. Nine studies
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included in this review reported decreases in HIV preva-
lence, and three reported decreases in HIV incidence. All
studies were non-randomized before-after comparisons or
interrupted time series analyses, and most showed
evidence of potential selection biases. The authors con-
cluded that these results support NSP as a structural-level
intervention to reduce population-level infection.
Four older published reviews with qualitative synthesis
and an overall unclear or high risk of bias reported
mixed findings regarding the impact of NSP on HIV in-
cidence/prevalence. These reviews provide a historical
perspective on the evolution of NSP implementation
and evaluation. The first published review by Leonard
et al. [25], was an update of a previous systematic
review. Gibson et al. [35] included six studies published
up to 1999 with a range of study designs, participants
and settings, reporting on HIV outcomes. The Institute
of Medicine’s evidence report [24], identified 12 relevant
studies, including cohort, case-control and ecological
designs, as well as studies using mathematical models.
Finally, the review by Kall et al. [30] included 16 studies
published up to 2005, only two of which were not
included in other reviews from this overview.
All these reviews included landmark prospective
cohort studies conducted in Montreal and Vancouver in
the 1990s [39, 40], which found an association between
NSP participation and higher risk of HIV seroconver-
sion. This led Leonard et al. to conclude that there was
methodologically weak evidence that NSP were not as
effective as previously found in modifying HIV preva-
lence and incidence among PWID. Kall et al. used vote
counting and reported that on most studies assessing
seroincidence the effect of NSP was not significant,
while four studies investigating seroprevalence at base-
line were unfavourable to NSP. The authors also stated
that in studies that found positive effects, confounders
had not been adequately controlled for. However, based
on epidemiological evidence that accumulated progres-
sively, authors of the other reviews highlighted a
number of selection biases that could account for
these findings, including: the inclusion of high-risk
cocaine injectors, who injected more often than
heroin users; the limited number of needles and sy-
ringes that users could have access to in early NSP;
and the ready availability of clean injecting equipment
through pharmacies which could have attracted
marginalized, particularly high-risk individuals.
Follow-up studies in the same settings, conducted after
expanding and adjusting NSP (e.g. by allowing unlimited
distribution of needles/syringes, increasing the number of
access points, and offering different distribution methods),
found no such increase in risk, or a decrease in HIV
prevalence. Gibson et al. [35] used vote counting and con-
sidered there was substantial evidence that NSP were
effective in preventing HIV seroconversion. Tilson et al.
[24] included four ecological studies that found an associ-
ation between HIV prevention programmes that include
NSP with reduced prevalence of HIV in urban settings.
Based on the weakness of these studies designs, this evi-
dence was considered modest using a modified GRADE
approach. Further, moderate evidence was found that
multi-component HIV prevention programmes that in-
clude NSP reduce intermediate HIV risk behaviour.
The Institute of Medicine report highlighted how almost
all published studies originate in North America, Western
Europe, and Australia [24]. Two additional reviews were
restricted to specific populations by geographical or
economical source. Hong and Li summarized evidence
from two studies conducted solely in China [31], while
Des Jarlais et al. focused on 13 studies of 11 NSPs with
high-coverage conducted in low/middle-income countries
[28]. In both cases, results from included studies generally
supported the effectiveness of NSP in reducing HIV. Des
Jarlais et al. reported a reduction of HIV prevalence in
four studies (from −3% to −15%), of estimated HIV inci-
dence in three studies (from −11/100 to −16/100 person-
years at risk), and of newly reported nationwide cases in
three national reports (from −30% to −93.3%). Conversely,
increases in HIV prevalence were found in two studies
(from +5.6% to +15.8%) and one national report (+37.6%)
included in the review by Des Jarlais et al. The authors
considered that, if high coverage is achieved, NSP appear
to be as effective in low/middle-income as in high-income
countries [28].
HCV prevalence and/or incidence
Eight included reviews synthesized the evidence on the
use of NSP in preventing HCV prevention in PWID. One
was rated as being at low [12], three at unclear [24, 25, 29]
and four at high risk of bias [28, 32–34], including two
reviews that used meta-analysis [32, 34]. The proportion
of studies included exclusively in one of these reviews was
88%. Both reviews with quantitative and qualitative
synthesis showed mixed results.
Reviews with meta-analysis Two reviews [32, 34], both
published in 2011 and rated as being at high risk of bias,
used meta-analysis.
Hagan et al. [34] included 7 studies focusing on NSP
and HCV outcomes (6 cohort and 1 case-control study),
all from North America. The pooled analysis of all studies,
using random effects models and with all measures of
effect converted to relative risks, showed an increase in
the risk of HCV acquisition with NSP (relative risk, 1.62;
95% CI: 1.04 to 2.52). There was considerable heterogen-
eity (I2 = 81%), but no subgroup or sensitivity analyses
were performed, and study quality was not explicitly
reported or considered in the analysis. Authors cautioned
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against possible volunteer bias in studies which found an
association between HCV acquisition and stand-alone
NSP participation, given that exchange programmes
attract and retain higher-risk PWID.
The second review by Turner et al. performed individual
participant-data meta-analysis based on studies solely
conducted in the UK [32]. High NSP coverage (100%
versus <100% needles per injection) reduced the risk of
new HCV infection (adjusted odds ratio 0.48; 95% CI: 0.25
to 0.93) (n = 833 participants, from 3 studies). Full harm
reduction (on opiate substitution treatment plus high NSP
coverage) further reduced the odds of new HCV infection
(adjusted odds ratio 0.21; 95% CI: 0.08 to 0.52). Results
were adjusted for gender, homelessness, crack injection
and duration of injection.
Reviews without meta-analysis Earlier reviews with
qualitative synthesis included many studies which were
not included in the previously mentioned reviews with
meta-analysis. These reviews reported mixed results
mostly summarized using vote counting, and we found
distinct interpretations of findings. We first present the
main results of reviews that focused on the influence of
different aspects of NSP provision, and then results of
reviews focusing exclusively on the comparison of NSP
versus no NSP intervention.
The low risk of bias review by Jones et al. [12] focused
on the impact of different aspects of NSP provision and
included two studies with HCV outcomes. Both of these
studies also included HIV outcomes, and results were
consistent for both infections: no difference in HCV
prevalence was found when comparing primary sources
of needles (pharmacies, fixed site NSP and van-based
NSP), and a full harm reduction intervention (including
NSP with opiate replacement therapy) was found to
reduce the incidence of HCV when compared to no
harm reduction (incidence rate of 3.5/100 person-years
vs. 23.2/100 person-years with an incidence rate ratio of
0.15; 95% CI: 0.06 to 0.40) [38].
The most recent review by Abdul-Quader et al. [29],
classified as having an unclear risk of bias, included six
structural intervention studies with before-after design
and outcome data on HCV biomarkers published up to
2011, all of which reported a reduction in HCV prevalence
after NSP implementation. It should be noted, as
described above, that these studies were restricted to NSP
with high-coverage based on the number of syringes dis-
tributed and the number of PWID in the local population,
and that only studies with pharmacy sales in conjunction
with NSP were included (and not programmes exclusively
focused on pharmacy sale or distribution).
While mostly focused on HIV and IRB outcomes, the
Institute of Medicine’s report from 2006 [24] also con-
sidered the impact of NSP on HCV prevention. Five
studies provided moderate evidence (adjusted GRADE)
that NSP had significantly less impact on transmission
and acquisition of HCV than on HIV, which was attrib-
uted by study authors to the apparent failure of these
programmes in providing other injecting equipment.
There was however one case-control study that showed
a considerable decrease in HCV acquisition. Another of
these earlier reviews, by Wright et al. [33] based on a
World Health Organization review [41], included 12
relevant studies. Authors highlighted how included
observational studies from Europe and Australia showed
statistically significant reductions in anti-HCV preva-
lence or incidence in the early 1990s (shortly after the
introduction of NSP), but the trend did not continue in
the following years. Also, reported negative studies
conducted in the US failed to identify an association
between NSP and HCV incidence. On the other hand,
two studies with expanded harm reduction included in
this review, demonstrated a statistically significant
reduction in HCV. Authors of this review concluded
that a more effective response to HCV prevention in
drug users should include provision of new interven-
tions, such as behavioural interventions and distribution
of other injecting paraphernalia alongside needle
injection material.
The earliest review, by Leonard and colleagues [25],
focused on three studies which, similarly to HIV out-
comes, provided conflicting and methodologically weak
evidence that NSP were not associated with decreases in
the risk of new infections with HCV (one earlier study
showing reduced transmission, and two later studies fail-
ing to show any association).
Regarding low/middle-income and transitional-economy
countries, Jarlais and colleagues [28] reviewed four
relevant studies, and found a decrease in HCV prevalence
(range − 4.2% to −10.2%) in three of those studies, while
HCV incidence remained stable in the fourth study. The
authors considered that, as with HIV, if high coverage was
achieved, NSP appeared to be as effective as in high-
income countries.
Injecting risk behaviours
Six reviews reported data on IRB outcomes. One was
at low risk of bias [12], two were at unclear [24, 25]
and three at high risk of bias [26, 32, 35]. Two
reviews performed meta-analysis [26, 32]. Specific IRB
outcomes reported by each review and study varied.
The proportion of studies included in only one of
these six reviews was 77%.
Reviews with meta-analysis The systematic review by
Turner et al. [32], considered to be at high risk of bias,
included an individual participant-data meta-analysis
reporting UK study data on self-reported IRB outcomes
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of needle sharing and mean number of injections in the
last month. Full harm reduction strategy was associ-
ated with a reduced risk in both of these outcomes,
with an adjusted odds ratio of 0.52 (95% CI: 0.32 to
0.83) for the former, and an adjusted mean difference
of −20.8 (95% CI: -27.3 to −14.4) for the latter (both
n = 2143 participants).
An earlier review by Cross et al. [26], classified as
having high risk of bias, pooled data from 10 studies
(one RCT and nine observational studies) published up
to 1995 across a range of IRB outcomes, including
sharing and lending syringes, condom use, injecting fre-
quency and bleach use. NSP were effective in reducing
high risk drug use and sexual behaviours (weighted
group mean 0.28; 95% CI, 0.21 to 0.35) (n = 1675). The
magnitude of the effect size was affected by outcome
and study design: the largest group effect of NSP was to
reduce sharing, followed by lending and injecting, and
results from pre-post-test designs showed larger effects
than the randomized study.
Reviews without meta-analysis The review by Jones et
al. provided relevant study results on the possible
influence of different aspects of NSP provision on IRB
outcomes [12]. Two poor quality studies included in this
review found that higher syringe coverage and participa-
tion in opiate substitution therapy alongside NSP
reduced injection risk behaviours among drug users.
Further, one cohort study and one cross-sectional study
suggested that PWID who obtained their needles exclu-
sively from NSP were less likely to engage in high risk
behaviours than those who obtained them via secondary
distribution, and in turn the latter had less IRB than
those who obtained no needles directly or indirectly
from NSP. On the other hand, evidence from two RCTs
also included in Jones et al. review suggested that NSP
setting does not impact on injection risk behaviours.
One of these trials compared pharmacy sales only with
NSP exchange plus pharmacy sales [42], and the other
compared hospital and community-based NSP [43]. As
supplementary evidence, three poor quality cross-
sectional studies found that mobile van sites and
vending machines may attract younger PWID with
higher risk profiles. Finally, evidence from three cross-
sectional studies, also included in this review, suggested
that syringe dispensation policies had a limited impact
on behavioural outcomes such as sharing, but some
impact on syringe re-use.
Reviews with narrative summaries provided largely
similar results regarding the overall effect of NSP. Tilson
et al. included 18 cohorts in their systematic review that
examined the impact of NSP on drug-related risks [24].
Thirteen studies found a reduction in self-reported
needle sharing. One study found injection frequency to
decrease, and four other studies showed no difference in
this outcome. Authors cautioned that nearly all pro-
grammes combined needle and syringe exchange with
other components such as outreach, risk reduction
education, condom distribution, bleach distribution,
education on needle disinfection, and referrals to sub-
stance abuse treatment and other health and social
services. Evidence was judged to be moderate (adjusted
GRADE). The authors reviewed the evidence for
pharmacy sales and physician-based prescriptions and
concluded that pharmacy dispensation, free of criminal
penalty, was an alternative strategy to make sterile
needles and syringes available to PWID.
Two earlier reviews [25, 35], already described in the
previous sections of the results, also analysed IRB
outcomes. Gibson et al. identified 23 studies published
up to 1999, and using vote counting concluded that
there was substantial evidence that NSP are effective in
preventing IRB. Leonard et al. reviewed 19 low quality
primary studies and evidence supported an effect of NSP
in modifying risk related injection practices.
Discussion
Summary of main results
In this overview of systematic reviews examining the ef-
fectiveness of NSP for PWID in reducing blood-borne
infection transmission and injecting risk behaviours, we
identified 13 systematic reviews contributing with 133
unique studies, which were mostly observational.
Methods used in these reviews varied at all levels of
review design and conduct. Only two reviews were
considered to have low risk of bias by reviewers [12, 27]
and most included studies were evaluated as having low
methodological quality. The quality of evidence, when
assessed, was considered low or modest to moderate.
Nine reviews reported outcome data on HIV prevalence/
incidence, eight on HCV, and six on IRB. Meta-analysis
was performed in four of these reviews.
Our interpretation of the findings is that the overall
results of the included systematic reviews are supportive
of the effectiveness of NSP in reducing HIV transmission
and IRB among PWID, as well as in reducing HCV in-
fection, although the latter to lesser extent. The overall
quality of the evidence is higher for HIV transmission
and IRB than for HCV infection. However, for HCV in-
fection, the strength of the evidence increases (because
studies’ results are more consistent) if the intervention
under consideration is not solely NSP, but includes other
components such as opiate replacement treatment, in a
strategy of full harm reduction intervention.
Furthermore it is well known that sharing other inject-
ing equipment (e.g. swabs, cookers, water and filters) is
an important route of transmission of blood-borne
infections, particularly in the case of HCV. In addition,
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clean injecting equipment is also available through
sources other than NSP (dilution bias) [44, 45]. This
overview did not identify any studies evaluating the
effects of paraphernalia distribution at reducing the
incidence or prevalence of HCV. One further aspect is
that individual NSP intervention studies are prone to
selection (volunteer) bias, as these exchange pro-
grammes attract and retain higher-risk PWID. Taken
together, these aspects may have contributed to some
mixed results reported in the systematic reviews and
individual studies addressing HCV infection.
To sum up, aspects of NSP provision may be relevant,
including structural-level NSP (i.e. high-level coverage),
and multi-component programmes including full harm
reduction seem to benefit all outcomes more than
individual NSP.
Overall completeness and applicability of evidence
In this field of public health, interventions and results
are highly influenced by economic, legal, ethical, social
and cultural circumstances. In the past, results from
some of the included studies led to major political deci-
sions and fuelled controversial debates, particularly in
the US. There are considerable differences in perspec-
tives regarding the role and provision of harm reduction
services, which impact study design and conduct and
selection of participants, and thus affect the validity and
generalizability of study results. This may at least
partially explain why we found heterogeneity in study
results and time trends, although there was consistency
in many outcomes. Further, while the majority of the
published research presented in different reviews origi-
nated from North America and Europe, one of the
reviews [28] supported part of these results for both high
and low/middle-income countries. Importantly, provision
of NSP interventions is low at a global level, particularly
in countries where the incidence and prevalence of both
HIV and HCV is highest.
Aspects of NSP provision are also key to decision-
making, and few included reviews examined how differ-
ent types of NSP provision impact on effectiveness. NSP
are extremely diverse in their design, staffing, character-
istics of participants, operation and programme delivery
policies. Further, PWID are diverse populations with
different preferences, behaviours, and life circumstances,
who often have difficulty in accessing formal healthcare
services. As such, the potential impact of NSP in redu-
cing injecting related-harms is limited by the extent to
which the programmes provide effective access to sterile
injecting equipment and other services, and are there-
fore able to attract their potential clients [46, 47].
Results from this overview support the importance of
high-level coverage and comprehensive services pro-
vided by many NSP in reducing bloodborne infections
and risk behaviours. We should note that outcomes
which were not included in this review may be relevant
to evaluate possible benefits of NSP. For example, phar-
macy access to sterile needles and syringes has been
found to provide specific benefits in addition to those
available through specialist NSPs [12]. Importantly, the
coexistence of different modes of injecting equipment
delivery, as well as tailoring services offered at different
venues, addresses several barriers encountered by PWID,
as modalities for improving syringe availability are likely
complementary and not competitive [48–50].
The additional benefits provided through this com-
plementary role of pharmacies may have prompted
Governments of Australia, Ireland, Spain (Basque
Country) and UK to remunerate pharmacies for the
important public health role provided through NSP
[8, 51–55]. As pharmacy-based NSP gradually expand,
it is important to pursue future research with a focus
on this setting.
Quality of the evidence
The results hereby presented have to be treated with
considerable caution. The methodological quality of the
included systematic reviews varied, but a majority of
reviews were considered to be at high risk of bias. Im-
portantly, we found considerable heterogeneity and inad-
equacies in methods used by different reviews, at all
stages of the design, conduct and reporting of the
review. Differences between eligibility criteria and search
and screening methods likely explain a striking mis-
match between included studies, despite some reviews
having similar research questions and covering relatively
close publication periods. Assessment of quality of in-
cluded studies was seldom performed, with the use of
different tools for assessment of risk of bias, some of
which were developed ad hoc with no validation, and
hardly any use of grading of quality of evidence. We also
found variability in the decision as to whether or not to
perform quantitative synthesis, even when the body of
evidence was similar. Few review authors chose to
present pooled estimates from meta-analyses, and when
present, there was variation in models, choice of
outcome measures and use of sensitivity and subgroup
analyses. Other authors opted to present narrative sum-
maries of results, often with vote counting, but there
were discrepancies in the interpretation of trial results.
Thus, there were obstacles in summarizing, comparing
and synthesizing results from all included reviews.
These factors also reflect the challenges that review
authors had in summarizing results from individual
studies, most of which were judged to be of low meth-
odological quality. Classification of study design was
discrepant between reviews, but most studies were
observational, at either individual or population-level.
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These designs are limited in establishing causality, and we
found different approaches regarding adjustment for
possible mediators and confounders. Further, a range of
selection biases were identified and explored in some
landmark studies, including volunteer bias of highest risk
users into NSP. Less biased evaluations of NSP would re-
quire the use of randomization, for example at a cluster
level, but there are many ethical, scientific and practical
challenges. Other aspects to consider are the challenges in
selecting, comparing and pooling different outcome mea-
sures and measurement tools when assessing HIV and
HCV infection, as well as needle and syringe sharing and
injecting frequency. A final limitation of this body of
evidence is that studies generally were not designed to
allow for separate examination of different aspects of NSP
provision. As most public health interventions, NSP are
complex health interventions with several interacting
components, multilevel factors (users, providers, setting,
health systems), and some degree of flexibility of interven-
tions allowed in the real-world setting. Hence, challenges
will likely persist in identifying the independent contribu-
tion of improving access to sterile needles and syringes,
both at review and individual study level.
Agreements and disagreements with other reviews and
potential biases
Two other overviews of reviews were published on this
topic [12, 14]. The first overview, published in 2008 [12],
was undertaken as a section of an extensive review of
the effectiveness and cost-effectiveness of NSPs for
PWID to inform guidance on the optimal provision of
NSPs from the perspective of the UK National Health
Service. The authors concluded that none of the in-
cluded systematic reviews examined HCV in any depth
and that there was insufficient evidence to support the
effectiveness of NPS on HCV incidence/prevalence. On
the other hand, there was tentative and sufficient
evidence to support the effectiveness of NSP on HIV in-
cidence/prevalence and on self-reported IRB, respect-
ively. The second overview was an updated overview
published in 2014 [13, 14] and focused on the effective-
ness of different harm reduction interventions, including
NSP, in preventing IRB, HIV and HCV transmission
among PWID [14]. This review was related to guidance
from the European Centre for Disease Prevention and
Control and the European Monitoring Centre for Drugs
and Drug Addiction. Taking into consideration the indi-
vidual conclusions of the core included systematic
reviews, as well as the number of individual studies
showing positive findings (i.e. a reduction of IRB, HIV
and/or HCV incidence/prevalence), the authors
concluded that there was: 1) sufficient review-level evi-
dence of effectiveness in relation to IRB; 2) tentative
review-level evidence to support the effectiveness of
NSP in reducing HIV transmission among PWID; and 3)
insufficient review-level evidence to support the effect-
iveness of NSP in reducing HCV transmission.
The field of overviews is relatively new, and this type
of study design has been gaining momentum as a valu-
able knowledge synthesis methodology that can collate
extensive information to facilitate the uptake and
application of knowledge by decision-makers [56]. How-
ever, published overviews show considerable variation in
their methods and reporting due to the unique meth-
odological challenges inherent in summarizing and
synthesizing evidence from different heterogeneous
sources [57, 58]. Reviews in public health pose additional
challenges, as methods are likely to vary more, with less
quantitative analysis and different approaches to synthe-
sizing and interpreting evidence.
Previous overviews have used different approaches to
review eligibility, selection, quality assessment and ana-
lysis. Also, there were differences in the framework used
to classify included reviews (e.g. core/supplementary),
the type of summary and synthesis used (e.g. vote count-
ing according to study or review results), and the
conclusions and evidence statements. In comparison, the
strengths of our overview include the use of strict eligi-
bility criteria, the evaluation of methodological quality of
included systematic reviews, and the categorization of
review by type of analysis and outcome. We used the
novel ROBIS tool [19], which was developed and
validated to overcome limitations seen in previous
instruments to assess the conduct and reporting of sys-
tematic reviews. This tool allowed us to stratify review
quality using clear and transparent criteria, thus provid-
ing support to our confidence in each review’s findings.
Further, by presenting pooled estimates of the effect of
NSP in different outcomes taken from reviews that per-
formed meta-analysis, we provide the opportunity for
readers to quantify the direction and magnitude of this
effect. We also highlight the need to use this quantitative
data to assess the likely relevance of findings.
There are a number of limitations to our overview.
While we identified and listed all unique studies
included in each review and assessed the degree of over-
lap between reviews, we did not assess these studies in-
dividually, as other overviews have [57]. We focused on
results from different reviews, which had some degree of
overlap, and thus have a risk of double counting results,
both for qualitative and quantitative reviews. Further,
the application of ROBIS was challenging, although
measures of agreement between raters were relatively
adequate, likely due to the use of piloted decision rules.
Conclusions
The findings of this overview of systematic reviews allow
the conclusion that there is moderate quality evidence
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that NSP is likely effective in reducing HIV transmission
and IRB among PWID, and that there is low to moder-
ate quality evidence that NSP in the context of a
comprehensive harm reduction strategy is likely effective
in reducing HCV infection. Full harm reduction inter-
ventions provided at structural level and in multi-
component programmes seem to be more beneficial.
The scarcity and the lack of robust quality of evidence
highlights the need for future community-level studies
of adequate design to support these conclusions, as well
as to address the impact of different aspects of NSP
provision. Future reviews and possibly overviews of
reviews should use standardized methods and frame-
works to improve comparability, synthesis and interpret-
ation of findings.
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